secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0000950170-23-058172
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics Q3 net loss $129.4M ($1.35/sh); SEQUOIA-HCM topline late Dec.
--------------------------------------------------------------------------

- Net loss for Q3 2023 was $129.4M ($1.35/diluted share) vs $142.3M ($1.52) in Q3 2022.
- Cash, cash equivalents and investments totaled $554.7M at Sep 30, 2023; received $50M milestone from Royalty Pharma.
- Q3 revenue dropped to $0.4M from $2.5M YoY; nine-month revenue $5.9M vs $92.6M prior.
- Topline results from pivotal Phase 3 SEQUOIA-HCM (aficamten in obstructive HCM) expected late December.
- Submitted formal dispute resolution to FDA regarding omecamtiv mecarbil CRL; EMA responses submitted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017023058172/0000950170-23-058172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017023058172/cytk-20231102.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-058172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer